Reframing the Hormone-Heart Debate
For more than two decades, the relationship between hormone therapy and cardiovascular health was dominated by fear — fear largely born from the 2002 Women’s Health Initiative (WHI) study, which reported increased cardiovascular events in women taking a specific oral estrogen-progestin combination. That finding reshaped prescribing habits globally, led millions of women to discontinue HRT, and created a generation of undertreated menopause.
But the science has evolved substantially. Revisited analyses of WHI data, combined with more than a dozen subsequent major studies, have produced a nuanced picture that is fundamentally more optimistic — particularly for the hormone therapy protocols used in modern clinical practice.
Testosterone and Men’s Cardiovascular Health
The cardiovascular picture for men on TRT has shifted dramatically over the past five years. The landmark TRAVERSE trial (Testosterone Replacement in Men with Hypogonadism) — a large, FDA-mandated, randomized controlled trial published in the New England Journal of Medicine in 2023 — found no increased risk of major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) in men with hypogonadism treated with testosterone gel compared to placebo over 22 months of follow-up.
Additionally, epidemiological data consistently shows that low testosterone in men is associated with:
- Higher cardiovascular disease incidence and mortality
- Increased visceral adiposity (abdominal fat — a major cardiovascular risk factor)
- Worsened lipid profiles (lower HDL, higher triglycerides)
- Increased insulin resistance and metabolic syndrome
- Higher inflammatory markers (CRP, IL-6)
- Higher rates of type 2 diabetes
Restoring testosterone to physiological levels has been shown to improve insulin sensitivity, reduce visceral fat, improve lipid profiles, reduce inflammatory markers, and improve blood pressure regulation in hypogonadal men — all cardiovascular risk factors that improve with treatment.
Estrogen and Women’s Cardiovascular Health: The Timing Hypothesis
The WHI finding was real but context-dependent. The study enrolled women with an average age of 63 — predominantly 10+ years past menopause — and used oral conjugated equine estrogen combined with synthetic progestin (medroxyprogesterone acetate). This is not the modern standard of care.
The “timing hypothesis” — now well-supported by multiple studies including the Kronos Early Estrogen Prevention Study (KEEPS) and ELITE trial — demonstrates that HRT started within 10 years of menopause (or before age 60) in healthy women significantly reduces cardiovascular disease risk. Cardiovascular benefits include:
- Preserved arterial wall flexibility and reduced atherosclerosis progression
- Improved lipid profiles (higher HDL, lower LDL)
- Reduced blood pressure and improved endothelial function
- Reduced insulin resistance
- Anti-inflammatory effects
Transdermal estrogen (patches, gels, creams) has an additional advantage over oral estrogen: it bypasses first-pass liver metabolism, avoiding the increase in clotting factors (particularly factor VII and fibrinogen) associated with oral preparations. This appears to eliminate the elevated stroke and venous thromboembolism risk seen with oral formulations.
The choice of progestogen also matters. Bioidentical micronized progesterone (unlike synthetic progestins) appears to be cardiovascularly neutral or beneficial, without the pro-thrombotic and adverse lipid effects seen with medroxyprogesterone acetate in the WHI.
What This Means for Patients at Multigen Wellness
The modern approach to hormone therapy — optimized timing, transdermal or injectable delivery, bioidentical compounds, individualized dosing with regular monitoring — carries a cardiovascular risk profile that is fundamentally different from the WHI study protocol. For appropriately screened, healthy patients starting therapy within the optimal window, the cardiovascular evidence is either neutral or favorable.
Every Multigen Wellness patient undergoes baseline cardiovascular screening including lipid panel, fasting glucose, blood pressure assessment, and relevant history review before hormone therapy is initiated. Monitoring at regular intervals ensures early identification of any parameters requiring dose adjustment.
Now Serving Round Rock, TX
MultiGen Wellness brings this same hormone therapy and cardiovascular health care to patients throughout Round Rock and the surrounding TX area. Through our online platform, Round Rock residents can complete lab work locally, meet with a licensed physician by telehealth, and start a personalized treatment plan without ever visiting an office in person.
If you have concerns about hormone therapy and heart health, our providers are prepared to discuss the full evidence picture with you. Call Multigen Wellness at (800) 259-0015 to schedule your consultation.